Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2020; 12(7): 768-781
Published online Jul 15, 2020. doi: 10.4251/wjgo.v12.i7.768
Published online Jul 15, 2020. doi: 10.4251/wjgo.v12.i7.768
Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer
Reiko Ashida, Tatsuya Ioka, Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan
Nobuyasu Fukutake, Ryoji Takada, Kazuyoshi Ohkawa, Kazuhiro Katayama, Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan
Hirofumi Akita, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
Hidenori Takahashi, Department of Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan
Shingo Ohira, Teruki Teshima, Department of Radiation Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan
Author contributions: Ashida R and Fukutake N designed the research; Ashida R, Fukutake N, Takada R, Ioka T, Ohkawa K, Katayama K, Akita H, Takahashi H, Ohira S and Teshima T performed the research; Teshima T contributed the grant; Ashida R, Fukutake N and Ohira S analyzed the data; Ashida R wrote the paper; All authors have read and agreed to the final manuscript.
Supported by the JSPS KAKENHI Grant [Grant-in Aid for Scientific Research (B)] , No. 15H04913 .
Institutional review board statement: The protocol of this study was approved by the Osaka International Cancer Institute Institutional Review Board.
Clinical trial registration statement: This registration policy applies to the prospective study only.
Informed consent statement: All study participants, or their legal guardians, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: Tatsuya Ioka received an advisor’s role and speaker’s fee from Taiho Pharmaceutical, and he also received a speaker’s fee from Yakult Honsha. The other authors declare no conflict of interests for this paper.
Data sharing statement: No additional data are available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Reiko Ashida, MD, PhD, Attending Doctor, Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan. rashida@goo.jp
Received: February 3, 2020
Peer-review started: February 3, 2020
First decision: March 24, 2020
Revised: April 13, 2020
Accepted: May 12, 2020
Article in press: May 12, 2020
Published online: July 15, 2020
Processing time: 163 Days and 6 Hours
Peer-review started: February 3, 2020
First decision: March 24, 2020
Revised: April 13, 2020
Accepted: May 12, 2020
Article in press: May 12, 2020
Published online: July 15, 2020
Processing time: 163 Days and 6 Hours
Core Tip
Core tip: Currently, chemoradiation therapy for pancreatic cancer is mainly performed for patients with unresectable or borderline resectable pancreatic cancer (RPC). Although image-guided radiation therapies rely on fiducial marker placement, no standard delivery method has been established, and the nature of RPC during chemoradiation therapy remains unclear. In the present study, we report the feasibility and safety of endoscopic ultrasound-guided fiducial marker placement for RPC as well as the specificity of RPC, including daily tumor positional changes, which are affected by not only respiration but also food intake, fluid intake and bowel condition.